29 Jan 2018 07:00
29 January 2018
Concepta plc
("Concepta" or the "Company")
Results of hospital evaluations of myLotus product in China
Concepta plc, (AIM: CPT) the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce the results of the hospital evaluations of its myLotus product in China, its launch market.
Over a 12 week period (August - November 2017) the myLotus ovulation tests and pregnancy urine tests were compared to laboratory blood tests in 2 locations: Changhai Hospital (Shanghai) and SJZ Reproductive Hospital (Shijiazhuang).
64 women participated in the LH** (ovulation) tests and 59 women in the hCG*** (pregnancy) tests.
The results of the hospital evaluations for ovulation testing showed 100% correlation between myLotus and laboratory blood tests. The evaluation also included a comparison with a leading home test. As myLotus also provides quantitative results, the evaluation showed that it is possible for women who commonly experience weaker positives to ascertain exactly when they are about to ovulate much more accurately in comparison to using the existing commercially available home tests.
The evaluations for pregnancy testing were equally impressive, with myLotus achieving a correlation of over 98% with blood tests.
Erik Henau, CEO of Concepta commented: "The traditional route to market for fertility testing in China is via the hospital channel. We are currently building a network of distributors for whom these test results are invaluable when presenting myLotus to doctors. The sheer volume of patients is overloading the Chinese healthcare system and with many women classified as experiencing 'unexplained infertility' these results give doctors the confidence to recommend that couples should use myLotus to help them increase their chances of conceiving.
"In many other markets, the route to market differs to that of China in that a direct-to-consumer approach is common for products such as ours. However, as we look to expand and launch myLotus in these additional markets, gaining medical endorsement for the product will be crucial in building consumer trust in these early stages of our brand development, as well as directly reassuring our customers of the product's capabilities. In this regard, we are currently discussing the possibility of publishing a peer-reviewed article in a medical journal with the principal investigators.*"
*All data is kept on file and published articles will be referenced on Concepta's website once approved for release.
Enquiries:
The Company
Erik Henau
CEO
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
NOVUM Securities Limited (Broker)
Colin Rowbury
+44 (0) 20 7399 9400
Yellow Jersey (Financial PR)
Georgia Colkin / Joe Burgess / Katie Bairsto
Tel: +44 (0) 776 932 5254
About Concepta Plc:
Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.
myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH** and hCG***hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.
Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.
The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.
*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.
** LH: Luteinising hormone is produced by the pituitary gland and is one of the main hormones that control the reproductive system.
*** hCG: Human chorionic gonadotropin is a hormone produced by the placenta after implantation and is an indicator of pregnancy.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.